CY1121190T1 - Δοσολογικη μορφη ανταγωνιστη υποδοχεα προγεστερονης - Google Patents

Δοσολογικη μορφη ανταγωνιστη υποδοχεα προγεστερονης

Info

Publication number
CY1121190T1
CY1121190T1 CY20191100113T CY191100113T CY1121190T1 CY 1121190 T1 CY1121190 T1 CY 1121190T1 CY 20191100113 T CY20191100113 T CY 20191100113T CY 191100113 T CY191100113 T CY 191100113T CY 1121190 T1 CY1121190 T1 CY 1121190T1
Authority
CY
Cyprus
Prior art keywords
dosage form
progesterone receptors
competitive progesterone
directed
pharmaceutical composition
Prior art date
Application number
CY20191100113T
Other languages
English (en)
Inventor
Barbara SCHÜTT
Marcus-Hillert SCHULTZE-MOSGAU
Andreas Kaiser
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48050601&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121190(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of CY1121190T1 publication Critical patent/CY1121190T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η εφεύρεση κατευθύνεται σε μια φαρμακευτική σύνθεση η οποία περιλαμβάνει έναν ανταγωνιστή υποδοχέα προγεστερόνης και συγκεκριμένα (11 β, 17β)-17-υδροξυ-11-[4-(μεθυλσουλφονυλ)φαινυλ]-17-(πενταφθοροαιθυλ)οιστρα-4,9-διεν-3-όνη σε δοσολογία περίπου 0,5 έως 5 mg και πιο συγκεκριμένα 2 mg. Επιπροσθέτως, η εφεύρεση κατευθύνεται στη χρήση μιας νέας φαρμακευτικής σύνθεσης για θεραπευτική αγωγή και/ή προφύλαξη των γυναικολογικών παθήσεων, όπως τα ινομυώματα της μήτρας (ινομυώματα, λειομύωμα μήτρας), ενδομητρίωση ή υπερβολική έμμηνο-αιμορραγία, και μέθοδος για τη λήψη μιας τέτοιας σύνθεσης και από του στόματος μορφή δοσολογίας.
CY20191100113T 2013-04-11 2019-01-24 Δοσολογικη μορφη ανταγωνιστη υποδοχεα προγεστερονης CY1121190T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13163417 2013-04-11
EP14715933.9A EP2983671B1 (en) 2013-04-11 2014-04-09 Progesterone receptor antagonist dosage form
PCT/EP2014/057101 WO2014166971A1 (en) 2013-04-11 2014-04-09 Progesterone receptor antagonist dosage form

Publications (1)

Publication Number Publication Date
CY1121190T1 true CY1121190T1 (el) 2020-05-29

Family

ID=48050601

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100113T CY1121190T1 (el) 2013-04-11 2019-01-24 Δοσολογικη μορφη ανταγωνιστη υποδοχεα προγεστερονης

Country Status (35)

Country Link
US (2) US20160296534A1 (el)
EP (1) EP2983671B1 (el)
JP (2) JP6486900B2 (el)
KR (1) KR102198059B1 (el)
CN (2) CN105120873A (el)
AP (1) AP2015008778A0 (el)
AR (1) AR095834A1 (el)
AU (1) AU2014253153B2 (el)
BR (1) BR112015025706A2 (el)
CA (1) CA2909121C (el)
CL (1) CL2015003014A1 (el)
CY (1) CY1121190T1 (el)
DK (1) DK2983671T3 (el)
EA (1) EA032481B1 (el)
ES (1) ES2708351T3 (el)
HK (1) HK1218069A1 (el)
HR (1) HRP20190141T1 (el)
HU (1) HUE042368T2 (el)
IL (1) IL241815B (el)
LT (1) LT2983671T (el)
MA (1) MA38465A1 (el)
MX (1) MX363979B (el)
MY (1) MY188267A (el)
PH (1) PH12015502326A1 (el)
PL (1) PL2983671T4 (el)
PT (1) PT2983671T (el)
RS (1) RS58277B1 (el)
SG (1) SG11201507935TA (el)
SI (1) SI2983671T1 (el)
TN (1) TN2015000454A1 (el)
TR (1) TR201900954T4 (el)
TW (2) TW201932116A (el)
UA (1) UA116471C2 (el)
WO (1) WO2014166971A1 (el)
ZA (1) ZA201801736B (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2017000482A1 (en) * 2015-05-18 2019-04-12 Bayer Pharma AG Selective progesterone receptor modulator (sprm) regimen.
EP3214092A1 (en) * 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one
EP3384913A1 (en) * 2017-04-03 2018-10-10 Bayer Pharma Aktiengesellschaft Selective progesterone receptor modulators and stabilized estrogen level in patient

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426601A1 (de) 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
DK0792152T3 (da) 1994-11-22 2004-07-12 Balance Pharmaceuticals Inc Fremgangsmåder til svangerskabsforebyggelse
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
PE20000129A1 (es) 1997-12-23 2000-03-11 Schering Ag 11 beta-halogeno-estratrienos sustituidos en 7 alfa, asi como el procedimiento para elaborar preparados farmaceuticos que contienen tales 11 beta-halogeno-estratrienos sustituidos en 7 alfa
US6476079B1 (en) 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
DE10159217A1 (de) 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
US8088758B2 (en) * 2003-11-12 2012-01-03 Abbott Products Gmbh 17β-hydroxysteroid dehydrogenase type I inhibitors
AU2005265357B2 (en) 2004-07-09 2011-04-07 Laboratoire Hra Pharma Sustained release compositions containing progesterone receptor modulators
DE102009034362A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) * 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) * 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) * 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten

Also Published As

Publication number Publication date
HUE042368T2 (hu) 2019-06-28
TW201517910A (zh) 2015-05-16
LT2983671T (lt) 2019-02-11
TWI672142B (zh) 2019-09-21
SI2983671T1 (sl) 2020-06-30
CL2015003014A1 (es) 2016-04-15
PL2983671T3 (pl) 2019-04-30
RS58277B1 (sr) 2019-03-29
AU2014253153A1 (en) 2015-10-15
PT2983671T (pt) 2019-02-25
KR102198059B1 (ko) 2021-01-05
NZ712670A (en) 2020-10-30
AU2014253153B2 (en) 2019-05-30
CN110051619A (zh) 2019-07-26
PL2983671T4 (pl) 2019-04-30
AR095834A1 (es) 2015-11-11
KR20150143595A (ko) 2015-12-23
MX363979B (es) 2019-04-08
PH12015502326A1 (en) 2016-02-10
SG11201507935TA (en) 2015-10-29
TR201900954T4 (tr) 2019-02-21
JP6486900B2 (ja) 2019-03-20
EA201501011A1 (ru) 2016-08-31
US20160296534A1 (en) 2016-10-13
WO2014166971A1 (en) 2014-10-16
MA38465A1 (fr) 2017-02-28
IL241815B (en) 2019-11-28
BR112015025706A2 (pt) 2017-07-18
EA032481B1 (ru) 2019-06-28
EP2983671A1 (en) 2016-02-17
UA116471C2 (uk) 2018-03-26
US20220143045A1 (en) 2022-05-12
TW201932116A (zh) 2019-08-16
JP6691193B2 (ja) 2020-04-28
ZA201801736B (en) 2019-07-31
JP2016515639A (ja) 2016-05-30
HRP20190141T1 (hr) 2019-03-22
JP2019034969A (ja) 2019-03-07
CA2909121C (en) 2021-02-09
CA2909121A1 (en) 2014-10-16
EP2983671B1 (en) 2018-10-24
MX2015014264A (es) 2016-03-01
ES2708351T3 (es) 2019-04-09
TN2015000454A1 (en) 2017-04-06
HK1218069A1 (zh) 2017-02-03
CN105120873A (zh) 2015-12-02
MY188267A (en) 2021-11-24
DK2983671T3 (en) 2019-02-18
AP2015008778A0 (en) 2015-09-30

Similar Documents

Publication Publication Date Title
CY1119661T1 (el) 17-υδροξυ-17-πενταφθοροαιθυλο-οιστρα-4,9(10)-διεν-11-αρυλο-παραγωγα, μεθοδοι για την παραγωγη αυτων και χρηση αυτων για την αγωγη παθησεων
CY1123388T1 (el) Υποκατεστημενου νικοτινιμιδιου αναστολεις της βτκ και παρασκευη αυτων και χρηση στη θεραπεια καρκινου, φλεγμονης και αυτοανοσης ασθενειας
CY1118407T1 (el) Αντισωματα εξουδετερωσης υποδοχεα προλακτινης και θεραπευτικη χρηση αυτων
CY1121190T1 (el) Δοσολογικη μορφη ανταγωνιστη υποδοχεα προγεστερονης
CY1120429T1 (el) Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
SG10201810154WA (en) Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
CY1119499T1 (el) Ενωσεις 6,7-διυδροπυραζολο[1,5-α]πυραζιν-4(5η)-ονης και η χρηση τους ως αρνητικοι αλλοστερικοι τροποποιητες των υποδοχεων mglur2
CY1116315T1 (el) Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
EA201291372A1 (ru) Фармацевтическая композиция, содержащая дроспиренон, и набор для предупреждения зачатия
EA201500851A1 (ru) ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3)
CY1125179T1 (el) Παραγωγα πυραζολιου χρησιμα ως αναστολεις της πρωτεïνης ενεργοποιησης της 5-λιποξυγενασης (flap)
CY1122731T1 (el) Διαμορφωτες υποδοχεα οιστρογονων
AR095691A1 (es) FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USO
PH12017502100A1 (en) Selective progesterone receptor modulator (sprm) regimen
EA201690077A1 (ru) Терапевтически активные производные эстратриен-тиазола
PA8848001A1 (es) Pirrolidinas
UY28334A1 (es) Composicion que comprende antagonistas de receptores de progesterona y antiestrógenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas.
EA201492238A1 (ru) Композиция мизопростола
TH163150B (th) รูปแบบยาของโพรเจสเทอโรนรีเซปเตอร์แอนตะกอนิสต์
TH163150A (th) รูปแบบยาของโพรเจสเทอโรนรีเซปเตอร์แอนตะกอนิสต์
CY1113127T1 (el) Οξα στεροειδη παραγωγα ως εκλεκτικοι τροποποιητες υποδοχεων προγεστερονης
UY30815A1 (es) Moduladores no esteroidales del receptor de progesterona
TH136245B (th) องค์ประกอบและวิธีการให้ยาออกฤทธิ์ต้านฮอร์โมนโปรเจสเตอโรน โดยไม่เป็นพิษ
NZ731834A (en) Compositions for use in treating heavy menstrual bleeding and uterine fibroids
CL2012001723A1 (es) Compuestos derivados de aminoalquilpirimidina, antagonistas del receptor h4 de histamina; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento o la prevencion de una enfermedad alergica; inmunologica o inflamatoria, del dolor o del cancer.